Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Liliemark

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Lakartidningen|November 9, 2016
Jan Liliemark
Seminars in Cancer Biology|June 5, 2017
From evidence-based to hope-based medicine? Ethical aspects on conditional market authorization of and early access to new cancer drugsLars Sandman, Jan Liliemark
Lakartidningen|July 9, 2009
[Biosimilar products comparable to original preparations. The Medical Products Agency will not yet classify the agents as generics]Mats Welin, Jan Liliemark
Hematology/Oncology Clinics of North America|September 23, 2006
Purine analogues: rationale for development, mechanisms of action, and pharmacokinetics in hairy cell leukemiaGunnar Juliusson, Jan Liliemark
Bioethics|December 12, 2018
Withholding and withdrawing treatment for cost-effectiveness reasons: Are they ethically on par?Lars Sandman, Jan Liliemark
Health Care Analysis : HCA : Journal of Health Philosophy and Policy|August 1, 2023
Should Severity Assessments in Healthcare Priority Setting be Risk- and Time-Sensitive?Lars Sandman, Jan Liliemark
Lakartidningen|October 18, 2017
Ragnar Levi, Jan Liliemark, Susanna Axelsson
Lakartidningen|July 28, 2005
[More information on drug package inserts and counseling replace the warning triangle]Björn Beermann, Jan Liliemark, Kurt Johansson
Medicine, Health Care, and Philosophy|June 1, 2024
Is a larger patient benefit always better in healthcare priority setting?Lars Sandman, Jan Liliemark, Erik Gustavsson, et al.
Lakartidningen|March 5, 2013
[More randomized studies in health care can be made cheaper and more regularly]Måns Rosén, Jan Adolfsson, Jan Liliemark, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Lakartidningen|November 9, 2016
Jan Liliemark
Seminars in Cancer Biology|June 5, 2017
From evidence-based to hope-based medicine? Ethical aspects on conditional market authorization of and early access to new cancer drugsLars Sandman, Jan Liliemark
Lakartidningen|July 9, 2009
[Biosimilar products comparable to original preparations. The Medical Products Agency will not yet classify the agents as generics]Mats Welin, Jan Liliemark
Hematology/Oncology Clinics of North America|September 23, 2006
Purine analogues: rationale for development, mechanisms of action, and pharmacokinetics in hairy cell leukemiaGunnar Juliusson, Jan Liliemark
Bioethics|December 12, 2018
Withholding and withdrawing treatment for cost-effectiveness reasons: Are they ethically on par?Lars Sandman, Jan Liliemark
Health Care Analysis : HCA : Journal of Health Philosophy and Policy|August 1, 2023
Should Severity Assessments in Healthcare Priority Setting be Risk- and Time-Sensitive?Lars Sandman, Jan Liliemark
Lakartidningen|October 18, 2017
Ragnar Levi, Jan Liliemark, Susanna Axelsson
Lakartidningen|July 28, 2005
[More information on drug package inserts and counseling replace the warning triangle]Björn Beermann, Jan Liliemark, Kurt Johansson
Medicine, Health Care, and Philosophy|June 1, 2024
Is a larger patient benefit always better in healthcare priority setting?Lars Sandman, Jan Liliemark, Erik Gustavsson, et al.
Lakartidningen|March 5, 2013
[More randomized studies in health care can be made cheaper and more regularly]Måns Rosén, Jan Adolfsson, Jan Liliemark, et al.
Pageof 3